TELA Stock Analysis
TE
Uncovered
TELA Bio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The firm's first portfolio of solutions offers four configurations of the OviTex Reinforced Tissue Matrix (OviTex) designed for hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. The firm's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. The OviTex products are sterile reinforced tissue matrices derived from ovine rumen with either polypropylene or polyglycolic acid (PGA). The firm's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.